Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: L02 • ACR Convergence 2021
COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune Diseases
Ines Colmegna¹, Mariana Useche¹, Emmanouil Rampakakis², Nathalie Amiable³, Emmanuelle Rollet-Labelle³, Louis Bessette⁴, Jo-Anne Costa⁴, Marc Dionne⁴, Mary-Ann Fitzcharles², Elizabeth Hazel², Deirdre McCormack², Laetitia Michou⁴, Pantelis Panopalis², Marc-Andre Langlois⁵, Sasha Bernatsky⁶ and Paul R. Fortin⁷, ¹The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²McGill University Health Centre, Montreal, QC, Canada, ³Centre de Recherche du CHU de Quebec, Quebec, Canada, ⁴Universite Laval, Quebec, QC, Canada, ⁵University of Ottawa, Ottawa, ON, Canada, ⁶McGill University, Montreal, QC, Canada, ⁷CHU de Quebec - Universite Laval, Quebec, Canada
Background/Purpose: Immunocompromised conditions and/or a history of autoimmune disease were exclusion criteria of the initial SARS-CoV-2 vaccines clinical trials. We assessed the safety and immunogenicity…
Abstract Number: L10 • ACR Convergence 2021
A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease
joshua solomon¹, Felix Woodhead², Sonye Danoff³, Shana Haynes-Harp⁴, Tanvi Naik⁵, Cathie Spino⁵, Shelley Hurwitz⁶, Rie Maurer⁶, Daniel Chambers⁷, Martin Kolb⁸, Hiliary Goldberg⁶ and Ivan Rosas⁴, ¹National Jewish Health, Denver, CO, ²University of Leicester, Leicester, United Kingdom, ³Johns Hopkins University, Baltimore, MD, ⁴Baylor College of Medicine, Houston, TX, ⁵University of Michigan, Ann Arbor, MI, ⁶Brigham and Womens Hospital, Boston, MA, ⁷University of Queensland, Brisbane, Australia, ⁸McMaster University, Hamilton, ON, Canada
Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a prevalent and morbid condition leading to premature death in 10% of those affected. The TRAIL1 trial…
Abstract Number: L11 • ACR Convergence 2021
Cardiovascular Risk of Hydroxychloroquine in the Treatment of Rheumatoid Arthritis: A Retrospective Cohort Study
ELVIRA D'ANDREA¹, Rishi Desai², Mengdong He³, Robert Glynn⁴, Hemin Lee², Michael Weinblatt², Daniel Solomon⁵ and Seoyoung Kim², ¹Brigham & Women's Hospital and Harvard Medical School, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³UCLA David Geffen School of Medicine, Los Angeles, CA, ⁴Brigham & Women's Hospital, Boston, MA, ⁵Brigham and Women's Hospital, Newton, MA
Background/Purpose: Hydroxychloroquine (HCQ) is a commonly used 1st-line disease-modifying antirheumatic drug (DMARD) for patients with rheumatoid arthritis (RA) in the U.S., while methotrexate (MTX) is…
Abstract Number: L01 • ACR Convergence 2021
Immunogenicity of mRNA COVID-19 Vaccines at 4 and 12 Weeks Post Full Vaccination in Patients with Inflammatory Rheumatic Diseases
Catherine Raptis¹, Diego Andrey², Christoph Berger³, Axel Finckh², Pierre Lescuyer², Adrian Ciurea⁴, Tanja Maletic¹, Christos Polysopoulos¹, Myriam Riek¹, Almut Scherer¹, Kim Lauper², Burkhard Moeller⁵, Judith Safford⁶, Sandra Schweizer⁷, Isabell von Loga¹, Nicolas Vuilleumier⁸ and Andrea Rubbert-Roth⁹, ¹SCQM Foundation, Zurich, Switzerland, ²Geneva University Hospital, Geneva, Switzerland, ³University Hospital Basel, Basel, Switzerland, ⁴University Hospital Zurich, Zrich, Switzerland, ⁵Inselspital - University Hospital Bern, Bern, Switzerland, ⁶RheumaCura Foundation, Zurich, Switzerland, ⁷Swiss League Against Rheumatism, Zurich, Switzerland, ⁸University Hospital of Geneva, Geneva, Switzerland, ⁹Kantonspital St Gallen, St.Gallen, Switzerland
Background/Purpose: Emerging evidence indicates that immunosuppressive therapies may result in reduced immunogenicity –and presumably reduced efficacy- following vaccination with mRNA COVID-19 vaccines but long-term data…
Abstract Number: 166 • 2020 Pediatric Rheumatology Symposium
Resident Memory T Cells in Human RA Synovium Display Restricted TCR Clones
Margaret Chang¹, Anais Levescot ², Nathan Nelson-Maney ³, Rachel Blaustein ⁴, Kellen Winden ¹, Allyn Morris ⁴, Spoorthi Balu ⁴, Alexandra Wactor ⁴, Kevin Wei ⁵, Lauren Henderson ⁶, Rachael Clark ⁴, Deepak Rao ⁴, Robert Fuhlbrigge ⁷ and Peter Nigrovic ⁸, ¹Boston Children's Hospital, Boston, ²Boston, ³, ⁴Brigham and Women's Hospital, Boston, ⁵BWH, Boston, ⁶Boston Children's Hospital, Watertown, Massachusetts, ⁷University of Colorado, Aurora, ⁸Boston Children's Hospital, Boston, Massachusetts
Background/Purpose: Resident memory T cells (TRM) are site-specific memory T cells that take up long-term residence in peripheral tissues and aid in pathogen defense. Dysregulated…
Abstract Number: L02 • 2019 ACR/ARP Annual Meeting
Multiple Industrial Air Pollutants and Anti-Citrullinated Protein Antibody Positivity
Naizhuo Zhao ¹, Audrey Smargiassi ², Marianne Hatzopoulou ³, Ines Colmegna ⁴, Marie Hudson ⁵, Marvin Fritzler ⁶, Philip Awadalla ⁷ and Sasha Bernatsky⁸, ¹Research Institute of the McGill University Health Centre, Montreal, Canada, ²University of Montreal, Montreal, Canada, ³University of Toronto, Toronto, Canada, ⁴McGill University Health Center, Montreal, QC, Canada, ⁵Jewish General Hospital, Lady Davis Institute for Medical Research, and Department of Medicine, McGill University, Montreal, Canada, ⁶Cumming School of Medicine, University of Calgary, Calgary, Canada, ⁷Ontario Institute for Cancer Research, Toronto, Canada, ⁸Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Studies of associations between industrial air emissions and rheumatic disease, or diseases-related serological biomarkers, are few. Moreover, previous evaluations typically studied individual (not mixed)…
Abstract Number: L12 • 2019 ACR/ARP Annual Meeting
Safety and Efficacy of Olokizumab in a Phase III Trial of Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate – CREDO1 Study
Evgeniy Nasonov ¹, Saeed Fatenejad ², Elena Korneva ³, Diana Krechikova ⁴, Alexey Maslyansky ⁵, Tatyana Plaksina ⁶, Marina Stanislav ⁷, Rumen Stoilov ⁸, Tamara Tyabut ⁹, Sergey Yakushin ¹⁰, Elena Zonova ¹¹ and Mark Genovese¹², ¹FSBSI "Scientific Research Institute of Rheumatology n.a. V.A. Nasonova", Moscow, Russia, ²SFC Medica, Charlotte, North Carolina, ³R-Pharm, Moscow, Russia, ⁴Non-governmental Healthcare Institution "Regional Clinical Hospital at Smolensk station of OJSC "Russian Railways, Smolensk, Russia, ⁵SBHI "North-West Federal Medical Research Center n.a. V.A.Almazov" of the Ministry of Healthcare of the Russian Federation, St-Petersburg, Russia, ⁶SBHI of Nizhny Novgorod Region "Nizhny Novgorod Regional Clinical Hospital n.a. P.A.Semashko", N.Novgorod, Russia, ⁷V.A. Nasonova Research Rheumatology Institute, Moscow, Russia, ⁸UMHAT St. Ivan Rilski, Clinic of Rheumatology, Sofia, Bulgaria, ⁹Belarusian Medical Academy of Postgraduate Education, City Clinical Hospital N1, Minsk, Belarus, ¹⁰Ryazan State Medical University, Ryazan, Russia, ¹¹Novosibirsk State Medical University, State Clinical Polyclinic 1, Novosibirsk, Russia, ¹²Stanford University, Stanford, CA
Background/Purpose: Olokizumab (OKZ) is a new humanized monoclonal antibody targeting IL-6 1, 2. Here we present the results of the first phase III study of…
Abstract Number: 4 • 2019 ACR/ARP Annual Meeting
AMP Deaminase 2 Surface Expression Counteracting CD73-Driven Generation of Anti-Inflammatory Extracellular Adenosine
Lisa Ehlers¹, Aditi Kuppe ¹, Cindy Strehl ¹, Marieluise Kirchner ², Frank Buttgereit ³ and Timo Gaber ¹, ¹Charite University Hospital Berlin, Berlin, Germany, ²Max Delbrück Center for Molecular Medicine, BIH Core Facility Proteomics, Berlin, Germany, ³Charité-Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Adenosine and its nucleotides represent crucial immunomodulators in the extracellular environment. ATP and ADP are released from stressed cells in states of inflammation, whereas…
Abstract Number: 57 • 2019 ACR/ARP Annual Meeting
Endothelial Progenitor Cells in the Pathophysiology of Interstitial Lung Disease Associated with Rheumatoid Arthritis
Veronica Pulito-Cueto¹, Sara Remuzgo-Martínez ¹, Fernanda Genre ¹, Leticia Lera-Gomez ¹, Veronica Mijares ¹, Pilar Alonso Lecue ², Victor Manuel Mora Cuesta ², David Iturbe ³, Sonia M. Fernández Rozas ², Ricardo Blanco ⁴, Alfonso Corrales ¹, Jose Manuel Cifrian Martínez ², Raquel López-Mejías ¹ and Miguel A Gonzalez-Gay ⁴, ¹Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, Santander, Spain, ²Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL; and Pneumology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain, Santander, Spain, ³Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain; and Pneumology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain, Santander, Spain, ⁴Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) is one of the most significant comorbidities that contributes to the increased mortality observed in patients with rheumatoid arthritis (RA)…
Abstract Number: 186 • 2019 ACR/ARP Annual Meeting
Asthma, Chronic Obstructive Pulmonary Disease, and Subsequent Risk for Incident Rheumatoid Arthritis Among Women: A Prospective Cohort Study
Julia Ford¹, Xinyi Liu ¹, Su H. Chu ², Bing Lu ¹, Michael Cho ¹, Edwin Silverman ¹, Karen Costenbader ¹, Carlos Camargo ³ and Jeffrey Sparks ¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Massachusetts General Hospital, Boston, MA
Background/Purpose: While RA patients are known to have excess respiratory morbidity and mortality, less is known about the role of chronic respiratory diseases in the…
Abstract Number: 276 • 2019 ACR/ARP Annual Meeting
Effectiveness of Screening by Nurse with Predetermined Questionnaire on Infections Before Administration of Intravenous Biologics in Patients with Rheumatoid Arthritis
Sayaka Furukawa¹, Sho Fukui ¹, Sakura Tamaki ², Tomoko Nakasone ³ and Masato Okada ⁴, ¹St.Luke's International Hospital, Chuo-ku, Tokyo, Japan, ²St. Luke's International Hospital, Chuo-ku, Japan, ³St. Luke's International Hospital, Chuo-ku, Tokyo, Japan, ⁴St. Luke's International Hospital, Tokyo, Japan
Background/Purpose: Biologics are widely used as treatment for rheumatoid arthritis (RA), and pre-administration screening of active infection is imperative for the safety use. There is…
Abstract Number: 446 • 2019 ACR/ARP Annual Meeting
High MDHAQ/RAPID3 (Multidimensional Health Assessment Questionnaire/Routine Assessment of Patient Index Data) Scores in RA Patients Who Have Depression According to a Screening Questionnaire
Rosa Morlà¹, Mariam Riad ², Raul Castellanos-Moreira ³, Virginia Ruiz-Esquide ⁴, Raimon Sanmarti ⁵, Jose Gomez-Puerta ⁶, Theodore Pincus ² and Isabel Castrejon ², ¹Rheumatology Unit, Xarxa Sanitaria Santa Tecla, Tarragona. Rheumatology, Fundacio Clinic, Barcelona, Barcelona, Spain, ²Division of Rheumatology, Rush University Medical Center, Chicago, IL, ³Rheumatology Department. Hospital Clínic Barcelona, Barcelona, Catalonia, Spain, ⁴Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Catalonia, Spain, ⁵Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Spain, ⁶Servei de Rheumatologia, Hospital Clinic Universtari, Barcelona, Barcelona, Catalonia, Spain
Background/Purpose: Depression in rheumatoid arthritis (RA) patients may be pre-existent, amplified, or may develop after the onset of RA1. The Patient Health Questionnaire (PHQ9) is…
Abstract Number: 472 • 2019 ACR/ARP Annual Meeting
Sleep Quality in Women with Rheumatoid Arthritis Is Associated with Disease Activity and Depressive Symptoms
Deborah Da Costa¹, Teresa Szlachetka ² and Diane Lacaille ³, ¹McGill University, Montreal, QC, Canada, ²University of British Columbia, Vancouver, BC, Canada, ³Arthritis Research Canada and University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Sleep disturbances, including difficulty initiating sleep, maintaining sleep, and/or early morningawakenings are prevalent in persons with rheumatoid arthritis (RA) and can significantly impact quality…
Abstract Number: 516 • 2019 ACR/ARP Annual Meeting
Impact of Baseline Demographics and Disease Activity on Outcomes in Patients with Rheumatoid Arthritis Receiving Upadacitinib
Michael Weinblatt¹, Eduardo Mysler ², Andrew Östör ³, Aaron Broadwell ⁴, Slawomir Jeka ⁵, Kendall Dunlap ⁶, Jessica Suboticki ⁶, Jose Jeffrey Enejosa ⁶, Barbara Hendrickson ⁶, Sheng Zhong ⁶, Katya Cherny ⁶ and Grace Wright ⁷, ¹Brigham and Women's Hospital, Boston, MA, USA, Boston, MA, ²Organización Medica de Investigación, Buenos Aires, Argentina, Buenos Aires, Argentina, ³Cabrini Medical Centre, Monash University, Malvern, Australia, Malvern, Australia, ⁴Rheumatology and Osteoporosis Specialists, Shreveport, LA, USA, Shreveport, LA, ⁵University Hospital Bydgoszcz no 2, CM UMK, Bydgoszcz, Poland, ⁶AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, ⁷New York University Langone Medical Center, New York, NY, USA, New York
Background/Purpose: Upadacitinib (UPA), an oral selective JAK1 inhibitor, has demonstrated favorable efficacy and acceptable safety in five Phase 3 global studies in patients with moderately…
Abstract Number: 815 • 2019 ACR/ARP Annual Meeting
Expression Profiling of Genes in Rheumatoid Fibroblast‑like Synoviocytes Regulated by Fas Ligand Using cDNA Microarray Analysis
Koji Fukuda¹, Yasushi Miura ², Shinya Hayashi ¹, Toshihisa Maeda ³ and Ryosuke Kuroda ¹, ¹Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan, ²Division of Orthopedic Science, Department Of Rehabilitation Science, Kobe University Graduate School of Health Sciences, Kobe, Japan, ³Matsubara Mayflower Hospital, Kobe, Japan
Background/Purpose: Fas ligand (FasL) is a member of tumor necrosis factor superfamily (TNFSF6) and reported to contribute to synovial hyperplasia of rheumatoid arthritis (RA). Apoptosis…

1
2
3
…
56
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.